ES2138691T3 - Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina. - Google Patents

Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.

Info

Publication number
ES2138691T3
ES2138691T3 ES95112521T ES95112521T ES2138691T3 ES 2138691 T3 ES2138691 T3 ES 2138691T3 ES 95112521 T ES95112521 T ES 95112521T ES 95112521 T ES95112521 T ES 95112521T ES 2138691 T3 ES2138691 T3 ES 2138691T3
Authority
ES
Spain
Prior art keywords
derivatives
fluorocitidina
acil
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95112521T
Other languages
English (en)
Inventor
Herbert Robert Brinkmann
Panayiotis Kalaritis
John Francis Morissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2138691T3 publication Critical patent/ES2138691T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE LOS AGENTES ANTITUMORALES CONOCIDOS N 4 -ACIL5''-DEOXI-5-FLUOROCITIDINA DE FORMULA:
ES95112521T 1994-08-26 1995-08-09 Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina. Expired - Lifetime ES2138691T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,842 US5476932A (en) 1994-08-26 1994-08-26 Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives

Publications (1)

Publication Number Publication Date
ES2138691T3 true ES2138691T3 (es) 2000-01-16

Family

ID=23143805

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95112521T Expired - Lifetime ES2138691T3 (es) 1994-08-26 1995-08-09 Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.

Country Status (9)

Country Link
US (1) US5476932A (es)
EP (1) EP0698611B1 (es)
JP (1) JP3986574B2 (es)
KR (1) KR100335542B1 (es)
CN (1) CN1053194C (es)
AT (1) ATE185811T1 (es)
DE (1) DE69512851T2 (es)
DK (1) DK0698611T3 (es)
ES (1) ES2138691T3 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
DE60326950D1 (de) 2002-05-15 2009-05-14 Janssen Pharmaceutica Nv N-substituierte tricyclische 3-aminopyrazole als pdgf rezeptorenhemmer
ATE402185T1 (de) * 2003-12-22 2008-08-15 Hoffmann La Roche Verfahren für fluorcytidinderivate
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
US20050192433A1 (en) * 2004-02-26 2005-09-01 Mitsui Chemicals, Inc. Metallic salt of N4-acylcytidine derivatives, and a method for producing N4-acylcytidine derivatives using the same
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
WO2009022435A1 (ja) * 2007-08-15 2009-02-19 Japan Absorbent Technology Institute 吸収体製品およびその製造方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
PL2300489T3 (pl) 2008-06-06 2016-11-30 Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) * 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
EP2416774B1 (en) 2009-04-06 2015-11-04 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
TR201808733T4 (tr) 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
CN104926901B (zh) * 2015-06-15 2018-04-20 广安凯特制药有限公司 一种卡培他滨关键中间体的合成方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3071512D1 (en) * 1980-09-22 1986-04-24 Towmotor Corp Carriage assembly with shiftable forks
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines

Also Published As

Publication number Publication date
US5476932A (en) 1995-12-19
DE69512851T2 (de) 2000-05-04
EP0698611B1 (en) 1999-10-20
CN1126726A (zh) 1996-07-17
DE69512851D1 (de) 1999-11-25
KR960007610A (ko) 1996-03-22
JPH0859687A (ja) 1996-03-05
ATE185811T1 (de) 1999-11-15
KR100335542B1 (ko) 2002-11-08
DK0698611T3 (da) 2000-03-27
EP0698611A1 (en) 1996-02-28
JP3986574B2 (ja) 2007-10-03
CN1053194C (zh) 2000-06-07

Similar Documents

Publication Publication Date Title
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2145318T3 (es) Imidazo(4,5-c)quinolin-aminas.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2196054T3 (es) Derivados de acido fenilacetico, procedimiento y productos intermedios para su obtencion y agentes que contienen los mismos.
NO912630L (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler som antiarteriosklerotiske midler
IT1285770B1 (it) Composti corticoidei
DE69127755D1 (de) Okulare hypotensive 2-dekarboxyl-2-aminoalkyl-prostaglandine
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
ES2109103T3 (es) Procedimiento para la preparacion de trialquilsilil-7 bacatina iii.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
ES2164765T3 (es) Heterociclilbenzonitrilos.
ES514852A0 (es) "procedimiento para la preparacion de nuevos derivados de ciclofosfamida".
DE69936052D1 (de) N1 modifizierte glycopeptide
ES522897A0 (es) "procedimiento para la preparacion de n-(2-metoxietil)-noroximorfona".
ES2166026T3 (es) Derivados de 1,2,3-benzotiadiazol y su uso como microbicidas.
ES508293A0 (es) "procedimiento para la preparacion de derivados de tiazolina".
MX174317B (es) Procedimiento para la preparacion de 1-hidroximetilpirazoles
MX9302878A (es) Procedimiento para la preparacion de un diaminodiol substituido.
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
MX10256A (es) Procedimiento para preparar nuevas 3-fenil-7h-tiazolo(3, 2-b) (1, 2, 4) triazin-7-onas.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
ES512921A0 (es) "procedimiento de preparacion de derivados de etanolamina".
ES516225A0 (es) "procedimiento para la preparacion de derivados de bis-aminometil-antraquinona".
ES522726A0 (es) "procedimiento para la preparacion de n-(2-metil--5-cloro-fenil)-n-metoxiacetil-3-amino-1,3-oxazilidin-urea"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 698611

Country of ref document: ES